Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The fifth volume of this series brings 5 reviews which cover the following topics: - Resistin: an irresistible therapeutic target for inflammatory diseases, allergy-related disorders, and cancer - Asthma in adults: evaluation, prevalence, and its clinical management - Nitrogen-containing heterocycles as anti-allergy agents - Experimental and clinical studies on the effects of nigella sativa and its constituents on allergic and immunological disorders - Aspirin desensitization/challenge in patients with cardiovascular diseases: current trends and advances Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.

This reference summarizes information about pharmaceuticals that can target infectious strains of coronaviruses to neutralize infections. Chapters focus on SARS-CoV-2, drug discovery methods and natural methods to combat the virus, which is a causative agent of COVID-19. Specifically, the book presents 5 chapters written by expert scholar on the following topics: Structure-Based Drug Discovery Approaches Applied to SARS-CoV-2 (the causative agent COVID- 19) Potential Antiviral Medicinal Plants against Novel SARS-CoV-2 Infections Caused by SARS Coronaviruses: Main Characteristics, Targets and Inhibitors Natural Sourced Traditional Indian and Chinese Medicines to Combat COVID- 19 Peptidomimetic and Peptide-Derived Agents Against 3CLpro from Coronaviruses The book contents present both conventional drug design and traditional approaches to discovering relevant drugs in an easy-to-read approach, which is supplemented by bibliographic references. It is intended as a reference for students (pharmacology, pharmacy) and researchers (virology) who are seeking information about antiviral drugs that can be used against coronaviruses.

The field of sleep medicine has gone through tremendous evolution since the discovery of REM sleep in 1953 and remarkable research in recent years has led to multiple advances in sleep medicine. Approvals for new medicines for treating sleep disorders along with new evidence-based interventions for insomnia and sleep apnea, have transformed sleep medicine into a medical specialty in its own right. The Latest Trends in Sleep Medicine reviews the most important improvements in sleep medicine, with contributions from over fifteen international and respected experts in the discipline. Ten chapters cover topics of interest to healthcare professionals who are focused on somnology such as the management of sleep disorders, restless leg syndrome, sleep apnea medication and surgery, REM sleep behavior disorder and cognitive behavioral therapy for insomnia. In addition to these topics in medicine, the contributors present broader picture of sleep medicine by reviewing secondary topics such as sleep and aging, and driving safety. The Latest Trends in Sleep Medicine will be useful to healthcare professionals seeking to improve their understanding about contemporary sleep medicine. It also serves as a timely update for respiratory and sleep medicine clinicians, whose efforts are still needed in treating and improving the quality and length of life in patients with complex sleep disorders. Audience: Healthcare professionals, residents and students in general, respiratory and sleep medicine sub specialties.

Advances in biochemistry, molecular biology, virology, and structural biology have enabled the researchers in veterinary medicine to make many exciting discoveries that have, in some cases, conceptually revolutionized our understanding of the discipline. Emerging Trends in Veterinary Virology is a review of selected topics about viral infections in animals. 11 chapters cover recent findings about specific viruses that infect a variety of hosts. The contents cover several types of veterinary infections in birds (Infectious laryngotracheitis (ILT), avian leucosis), cats (feline rabies), dogs (canine distemper), bovines (viral leukemia) and equines (hendra virus disease). Additionally, special topics such as the epidemiology of veterinary zoonoses and SARS are also covered. The book provides updated information for researchers (virologists, microbiologists), students and veterinarians, alike.

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels

The Evolution of Radionanotargeting towards Clinical Precision Oncology is a remarkable book honoring Professor Kalevi Kairemo, who is known among academic and medical circles as a pioneer in novel radiolabeled therapeutics. This festschrift provides an overview of key advances in the field of radionanotargeting, and the directions for future development in patient care. Prof Kairemo's research is based on multiomics, which involves multiple elements: genomics, transcriptomics, proteomics, metabolomics, microbiomics, epigenomics, exposome, imaging, and precision medicine, which is reflected by the unique collection of articles presented. The articles start from the angle of radionanotargeting and theragnostics leading to imaging and therapy, which includes sections for thyroid cancer, head and neck cancer, genitourinary cancers and neuroendocrine neoplasms. Theragnostics, nanoparticles and precision oncology have also been covered in their own segments, while also giving a glimpse of research in metabolic imaging, cardiovascular radionuclide imaging, and bone therapies. The sequence of chapters demonstrates how, through Professor Kairemo's efforts, radionanotargeting has evolved to a practice changing therapeutic approach in the clinic, particularly in oncology. Finally, Professor Kairemo's own memoir, Seven decades in health care and memoirs from colleagues including a personal introduction to him with a photographic cavalcade reveals the world of a multitasking person with a multidisciplinary approach to science, that ushered his development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine. This book is excellent for medical historians, trainees and specialists in clinical and radiological oncology in expanding their understanding of the role of radionuclide imaging over the years, making it an ideal tribute that belongs in the library of anyone involved in the field.

Osteosarcoma is a rare bone tumor that has a high incidence among children and young adults. Despite recent therapeutic developments, osteosarcoma still presents major hurdles to achieving successful results, mainly due to the presence of multi-drug-resistant cells. This monograph primarily aims to provide information about the basic science behind the treatment of osteosarcoma along with experimental results for a novel formulation that overcomes multidrug resistance, and therefore, may serve as a viable treatment option. The book starts with an updated and concise guide to the pathophysiology of the disease, while also introducing the reader to new therapies and materials (specifically chitosan, polyethyleneimine, poloxamers, poloxamines, and Pluronics®) used in the treatment process along with the aims of the experiments present subsequently. Next, the book documents the materials and methods used in developing polymeric micelles for delivering drugs to osteosarcoma sites. By explaining the basics of nanomedicine as a starting point, readers will understand how polymeric micelles act as facilitators of drug transport to cancer cells, and how one can synthesize a small stable micelle (by creating derivatives of base nanomaterials), capable of actively targeting osteosarcoma cells and overcoming multi-drug resistance. The chapter explains the synthesis and characterization techniques of the materials used to develop polymeric micelles. The results, a reflection of the conjugation of different experimental solutions initiated here, point to a modern route towards the search for a therapeutic solution for osteosarcoma. The simple, structured presentation coupled with relevant information on the subject of micelle-based nanotherapeutic drug delivery make this monograph an essential handbook for pharmaceutical scientists involved in the field of nanomedicine, drug delivery, cancer therapy and any researchers assisting specialists in clinical oncology for the treatment of osteosarcoma.

Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics have shown considerable potential and there is tremendous impetus for rapid translation from the pre-clinical to the clinical domain to significantly prolong the survival in HCC. In Nanotherapeutics for the Treatment of Hepatocellular Carcinoma, authoritative experts of the field have explored the important aspects of nanotherapeutics against HCC. The book exhaustively, vividly and explicitly describes the molecular pathogenesis, diagnostic aspects and nanotherapy of HCC, while also highlighting the challenges of conventional therapy and the benefits of nanotherapeutics. Chapters of the book also cover recent investigations of nanotherapeutics against HCC, types of nanomedicines, recent patents, commercially available nanotherapeutics and a future perspective to give a comprehensive review of the topic to readers. In addition to these defining features, the book provides several references for further reading. The book is an ideal resource on HCC nanotherapeutics for medical and pharmacology postgraduate students, faculties, researchers, and biomedical scientists working on HCC and nanotherapy.

Frontiers in Clinical Drug Research - Hematology is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies. Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research - Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology. The fifth volume of this series features 7 reviews with a focus on thalassemia treatment and preeclampsia among other topics. - Recent advances in the diagnosis and management of pulmonary embolism - An evidence-based approach to treatment with iron chelators in transfusion- dependent thalassemia patients: present trends and future scenario - Current and future treatments of iron overload in thalassemia patients - Preeclampsia: biological and clinical aspects - Haematological modulations by fixed dose combination (FDC) of tramadol hydrochloride/paracetamol (THP) - Possible use of eculizumab in critically ill patients infected with covid-19 role of complement c5, neutrophils, and nets in the induction DIC, sepsis, and MOF hematological markers - Emerging diagnostic and therapeutic targets in preeclampsia

Systemic lupus erythematosus (SLE) is an autoimmune disease. SLE affects many parts of the body, with joint pain in the knees and hands being commonly reported symptoms. Arthritis is, therefore, one of the most common symptoms of the disease. This book comprehensively summarizes information about SLE for medical professionals and students. The volume illustrates the process of making accurate diagnoses through systematic interpretation of ABCDEGFGI parameters: A (Alignment): malalignment and deformation; B (Bone): bone changes; C (Capsular lesions): cartilage and intra-articular lesions; D (Distribution): four dimensional distributions; E (Extra-bone): extra-articular soft tissue; F (Further information): further additional medical information; G (Goal): general analysis and integrated comprehensive diagnosis; H (Heal and Heath): treatment and prognosis; and I (Immunological analysis): immunological interpretations. Key Features: - Presents information about the clinical features of SLE and differential diagnosis through 11 chapters - Covers both rheumatic symptoms and systemic symptoms - Provides a comprehensive approach to SLE diagnosis and management which blends both rheumatology and radiology - Explains the ABCDEFGI system for diagnosing and treating SLE patients - Includes more than 750 detailed figures illustrating important information - Includes references for further reading The book is an informative resource for a wide range of scholarly and professional readers who may encounter SLE patients in clinical settings: rheumatologists, orthopedists, radiologists, physiatrists, immunologists, pediatricians, general physicians, medical technicians, caregivers and specialists in internal medicine.